Loading stock data…
INSM
$116.06-1.92 (-1.63%)
Market OpenUpdated 9:47 AM EDT
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insmed Incorporated in the Healthcare sector is trading at $116.06. Wall Street consensus targets $204.75 (20 analysts), implying a +76.4% move over the next 12 months. The stock is currently 45% below its 52-week high of $212.75, remaining 25.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +76.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$116.06
Potential Downside
0%
Whystock Fair Value$116.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$204.75+76.4%
Range$140.00 – $243.00
Fundamentals
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial l...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-139.97%
Volume
Today's trading volume
137,342
Recent News
Insmed Incorporated (INSM) Reports Q1 2026 Results
Insmed Incorporated (NASDAQ:INSM) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 7, Insmed Incorporated (NASDAQ:INSM) reported first-quarter 2026 financials. The company posted a total revenue of $306.0 million because of BRINSUPRI generating $207.9 million and ARIKAYCE contributing $98.1 million. BRINSUPRI revenue surged 44% sequentially from Q4 2025, while ARIKAYCE […]
Insmed (INSM) Soars on Bargain-Hunting After 10-Month Low
Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks With Stunning Gains. Insmed climbed by 11.66 percent on Tuesday to close at $116 apiece, as investors resorted to bargain-hunting after touching a 10-month low the day prior. On Monday, it can be recalled that the stock fell below the $100 territory, touching $98.90 at intra-day […]
Here's What Analysts Are Forecasting For Insmed Incorporated (NASDAQ:INSM) After Its First-Quarter Results
There's been a major selloff in Insmed Incorporated ( NASDAQ:INSM ) shares in the week since it released its quarterly...
Insmed Stock Sell-off is Overdone as Underlying Metrics Appear Positive, RBC Says
Insmed (INSM) stock sell-off post Q1 results is overdone as underlying metrics appear positive and p
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.